Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G earnings

This article was originally published in The Tan Sheet

Executive Summary

Prilosec OTC (omeprazole magnesium) helped drive Procter & Gamble's Health Care unit second-quarter net sales up 29% over the year-ago quarter to $2.64 bil., the firm announces Jan. 27. The healthcare segment, which was also boosted by Rx osteoporosis treatment Actonel, contributed significantly to the firm's 8% increase in organic sales for the quarter ended Dec. 31. Net sales for the period increased 27% to $18.34 bil., reflecting the Gillette acquisition completed in October. Despite Prilosec OTC's recent success, potential competitors are lining up. Novartis has licensed the switch rights toPrevacid (lansoprazole) from TAP and is eying a 2009 switch. Prilosec OTC will lose Hatch/Waxman marketing exclusivity in June, although patents listed in FDA's Orange Book extend through 2019. FDA cleared a suitability petition in July that opens the door for an ANDA application to market a generic version of Prilosec OTC in capsule form...

You may also be interested in...

Teva Takes On Amneal With Second US NuvaRing Rival

Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Government Report Outlines Costs, Savings Of Major Regs

The US HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts